IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

NCT06790706 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

154

Enrollment

OTHER

Sponsor class

Conditions

Peritoneal Mesothelioma
Gestational Trophoblastic Tumor
Thymoma and Thymic Carcinoma
Anaplastic Thyroid Carcinomas
Gastroenteropancreatic Neuroendocrine Tumor
Carcinoid Tumor

Interventions

DRUG: DOMVANALIMAB + ZIMBERELIMAB
DRUG: DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4

Sponsor

Hospices Civils de Lyon